Development of quantitative imaging mass spectrometry (q‐IMS) for drug visualization using animal tissues
Development of quantitative imaging mass spectrometry (q‐IMS) for drug visualization using animal tissues
复制标题
开发利用动物组织进行药物可视化的定量成像质谱（q-IMS）
DOI：
--
复制
发表时间：
2018
影响因子：
1.7
通讯作者：
S. Shimma
中科院分区：
文献类型：
--
作者：
E. Takeo;S. Shimma
定量成像质谱（q‐IMS）是药物分析研究的前沿课题。尽管已经报道了许多q - IMS方法，但对该方法的验证是不够的。我们研究了q - IMS与液相色谱-串联质谱（LC - MS/MS）耦合的可行性，以开发一种可验证的方法。该方法将LC - MS/MS定量信息与IMS获得的空间分布信息相结合。本文将测量的药物数量与IMS估计的药物数量进行了比较。靶向药物厄洛替尼是一种非小细胞肺癌的酪氨酸激酶抑制剂。我们的q - IMS方法在动物模型研究中的定量准确度约为17%。在厄洛替尼给药前后对小鼠肝脏和脑组织进行了测量。厄洛替尼被输送到大脑，尽管其浓度比肝脏中的浓度低104倍。
Quantitative imaging mass spectrometry (q‐IMS) is a frontier topic of research in drug analysis. Although many q‐IMS methodologies have been reported, validation of the method is insufficient. We have investigated the feasibility of coupling q‐IMS with liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) to develop a verifiable method. The approach combines quantitative LC‐MS/MS information with the spatial distribution information obtained by IMS. This paper compares measured drug quantities with those estimated using IMS. The target drug, erlotinib, is a tyrosine kinase inhibitor of non‐small‐cell lung cancer. The quantitative accuracy of our q‐IMS method in an animal model study is approximately 17%. Measurements were conducted on mouse liver and brain tissues before and after erlotinib administration. Erlotinib is delivered to the brain, although the concentration is 104 times smaller than that found in the liver.
绝对定量的MALDI成像质谱法：肝组织中利福平的一个病例。
影响因子：
7.4
作者：
Chumbley, Chad W.;Reyzer, Michelle L.;Allen, Jamie L.;Marriner, Gwendolyn A.;Via, Laura E.;Barry, Clifton E., III;Caprioli, Richard M.
通讯作者：
Caprioli, Richard M.
影响因子：
7.8
作者：
Sans M;Feider CL;Eberlin LS
通讯作者：
Eberlin LS
影响因子：
2.3
作者：
Reyzer, ML;Hsieh, YS;Caprioli, RM
通讯作者：
Caprioli, RM